Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses the impact of changes in lung function in patients with idiopathic pulmonary fibrosis (IPF). How does the rate of ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that two abstracts highlighting the clinical value of the company’s Envisia Genomic Classifier and Percepta ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Two differing nerandomilast doses were assessed against ...

Bexotegrast-treated patients demonstrated improvements in forced vital capacity (FVC) and reduced cough severity compared to placebo. Bexotegrast was well tolerated at 160 mg over 12 weeks of ...

Patients with SARD-ILD-PPF who continued nintedanib for 12 months or longer had better outcomes than those who discontinued therapy.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Oral nerandomilast doses of 9 mg and 18 mg were ...

Pulmonary function was significantly associated with frailty in community-dwelling older adults over a 5-year period, as indicated from data from more than 1000 individuals. The pulmonary function ...

If you have scarring in your lungs, you may have been diagnosed with pulmonary fibrosis. When the reason for this scarring is unknown, your condition is called idiopathic pulmonary fibrosis (IPF). You ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being ...